IperionX heads into its June 9 earnings report with something unusual in the critical minerals space: executives who put their own money on the table during the stock's February-to-March lows are now sitting on material unrealised gains — and the market is digesting a freshly confirmed Titan DFS.
The insider case is the standout. Executive Chairman Todd Hannigan and CEO Taso Arima each bought stock twice in late March and late April, when the share price traded between A$3.20 and A$4.50. Combined, the two men added over 1.28 million shares in open-market purchases across four transactions, committing roughly A$2.3 million of their own capital at the lows. The 90-day net insider position across the company is firmly in buying territory — 1.43 million shares at a net value of around US$4.1 million. That cluster of purchases, concentrated at the CEO and chairman level, is the clearest signal in the data that management sees the current valuation as underpriced relative to the project pipeline.
The sell-side has followed them upward. BTIG lifted its price target to A$55 on June 5 — raising its conviction just as the stock pulled back 6.9% over the past week to A$5.43. Bell Potter carries a Speculative Buy. The analyst price target mean of A$5.85 sits only modestly above the current price, but BTIG's aggressive A$55 target reflects the optionality bulls are pricing in around IperionX's U.S.-based rare earths and critical minerals project. The June 4 Titan DFS release confirmed high-return economics, which underpins the bull case: a domestic U.S. titanium and rare earths supply chain is structurally valuable in a trade-policy environment that rewards onshore critical minerals. Bears point to the opposite side of the ledger — the company remains pre-revenue, carries deeply negative return on assets and a low F-Score, and the stock is well off its cycle highs despite the strong 12-month relative performance.
Short positioning tells a moderate but steady story. Short interest has crept up to roughly 9% of free float — the highest level in recent weeks — rising about 1.6% over the past seven days. Days to cover runs near 19, which is elevated and reflects thin daily volume. Yet borrow availability is relatively comfortable at around 208% of short interest, meaning there is roughly twice as much stock available to borrow as there is currently shorted. Cost to borrow is 3.4%, up around 45% versus a week ago. That jump in borrow cost, combined with tightening availability (down about 5% over the week), suggests growing demand from new short-sellers — but at these levels, the borrow market is not under stress. The short score of 75.5 ranks near the top of the ORTEX universe and has held elevated for several weeks, reflecting a stock that carries meaningful short-seller conviction without tipping into outright squeeze territory.
Earnings history for IPX is volatile and asymmetric. The April 27 print drove an 8% one-day gain and a 14.5% five-day rally. The March events were severe — the March 12 announcement produced a 26% single-day decline and a 50% five-day collapse. That range of outcomes reflects how binary a development-stage critical minerals story can be: a production milestone or offtake update moves the stock sharply in either direction. Monday's print arrives against a backdrop of the Titan DFS release just days ago. Whether the market accepts that study's economics at face value — or demands firmer commercial progress — is the question the result will answer.
See the live data behind this article on ORTEX.
Open IPX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
